Depressive symptom profiles and severity patterns in outpatients with psychotic vs nonpsychotic major depression

Abstract

Background-Previous research suggests that patients with psychotic major depression (PMD) may differ from those with nonpsychotic major depression (NMD) not only in terms psychotic features, but also in their depressive symptom presentation. The present study contrasted the rates and severity of depressive symptoms in outpatients diagnosed with PMD versus NMD.

Exposure to Hypobaric Hypoxia and Reoxygenation Induces Transient Anxiety-Like Behavior in Rat

“…Depressive disorders are marked by chronic depressed mood, inability to experience pleasure, withdrawal of interest, feelings of worthlessness and suicidal tendencies [22,23]. Recent studies shows that stress induced disturbance in cognitive processes, especially impairment of learning and memory functions accelerate onset and development of depressive mood state [24,25].…”

Considerations on the ICD-11 Classification of Psychotic Depression

“…A typical case is a patient displaying anhedonia, psychomotor retardation, loss of interest, poor concentration and who is tormented by delusions of guilt, disease, worthlessness or impending disaster [10]. PD has a characteristic symptomatology which, apart from the psychotic features, involves a psychomotor disturbance (either agitation or retardation), rumination, insomnia [23,24], cognitive dysfunction and perplexity more often than non-PD [15,25,26,27]. A recent study has suggested that PD may also be accompanied by comorbid anxiety, somatoform and personality disorders more often than non-PD [28].…”

Do stress hormones connect environmental effects with behavior in the forced swim test?

“…Depression is a serious medical illness that is manifested by chronic depressed mood, the inability to experience pleasure, withdrawal of interest, feelings of worthlessness and suicidal tendencies [5][6][7]. To date psychobiological research on depression developed various pharmacological products such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors etc.…”